Table 1 Hazard ratios and mean proportions of women using adjuvant therapy in 1990–97 in different MISCAN models

From: Trends in the usage of adjuvant systemic therapy for breast cancer in the Netherlands and its effect on mortality

  Hazard ratio Proportion of women using adjuvant therapy (proportion of total number of women with breast cancer)
  N− N+ N− N+
Treatment and age     
Tamoxifen for 2 years, age <50 0.89a 0.81a 0.0b (16.0) 0.1b (13.0)
Tamoxifen for 2 years, age 50–69 0.89a 0.81a 0.065b (32.0) 0.78b (19.0)
Tamoxifen for 2 years, age 70+ 0.89a 0.81a 0.065b (12.0) 0.85b (8.0)
Chemotherapy, age <50 0.73a 0.73a 0.02b (16.0) 0.70b (13.0)
Chemotherapy, age 50–69 0.89* 0.89a 0.01b (32.0) 0.12b (19.0)
Chemotherapy, age 70+ 1.0 1.0 0.0b (12.0) 0.01b (8.0)
  1. aData were obtained from the 1998 Early Breast Cancer Trialists' Collaborative Group meta-analysis of clinical trials (EBCTCG, 1998a, b).
  2. bData were obtained from the NETB and the Eindhoven Cancer Registry.